Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.
Actively Recruiting
Researchers are evaluating the use of manual thrombus aspiration during primary percutaneous coronary intervention PCI in patients who have suffered a ST-segment Elevation Myocardial Infarction STEMI and have a high thrombus burden, defined as TIMI thrombus grade 3 or higher. This study aims to determine whether thrombus aspiration can reduce major cardiovascular events such as cardiovascular death, recurrent heart attacks, stent thrombosis, target vessel revascularization within 180 days, or stroke within 30 days after the procedure. Participants are randomly assigned in equal numbers to one of two groups one group receives upfront manual thrombus aspiration followed by PCI, while the other group undergoes PCI without thrombus aspiration. The procedures are performed within 12 hours of symptom onset. This open-label, multicenter trial compares the outcomes of these two approaches to better understand the potential benefits and risks of thrombus aspiration in this patient population. During the study, participants will be closely monitored for major adverse cardiovascular events up to 180 days after treatment, with additional assessments for stroke within 30 days and composite cardiocerebrovascular events up to one year. Researchers will collect clinical data to evaluate the effectiveness of the treatments. The total duration of participation includes these follow-up periods, ensuring thorough observation of safety and outcomes after the initial intervention.
Actively Recruiting
Researchers are evaluating the effects of nucresiran compared to placebo in patients with transthyretin amyloidosis with cardiomyopathy, a condition involving abnormal protein buildup in the heart. This study aims to assess whether nucresiran can reduce deaths from any cause and cardiovascular events, and also improve patient-reported health status and quality of life. The trial is a Phase 3, randomized, double-blind study focused on treatment outcomes. Participants will be randomly assigned to receive either nucresiran 300 mg or a placebo, both given as subcutaneous injections every six months during the double-blind period lasting up to 32 months with a maximum of 5 years. After this period, all participants enter an open-label extension where everyone receives nucresiran 300 mg every six months. Patients may continue some background therapies as decided by their investigators. Throughout the study, participants will be monitored for mortality and cardiovascular events, including hospitalizations and urgent heart failure visits. Health status and quality of life will be assessed using questionnaires. Safety and efficacy are evaluated through regular assessments during the double-blind phase and ongoing follow-up during the extension. The total study duration extends up to approximately 7 years, including follow-up after the main treatment period.